

Claims

1. A pharmaceutical composition for treating bone lesions in multiple myeloma which comprises as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma.

2. A pharmaceutical composition for treating bone lesions in multiple myeloma which comprises as an active ingredient 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.

3. A pharmaceutical composition for treating multiple myeloma which comprises as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma.

4. A pharmaceutical composition for treating multiple myeloma which comprises as an active ingredient 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.

5. A pharmaceutical composition as claimed in claim 2 or 4, which is for orally administration.

6. The pharmaceutical composition as claimed in claim 5 which is administered in a dose of 3 to 10 mg per day.

7. A method of treating bone lesions in multiple myeloma which comprises administering to a patient an effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma.

8. Use of an effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt, which has both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, for the production of a pharmaceutical composition for treating bone lesions in multiple myeloma.